{"title": "Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C", "author": null, "url": "https://www.fiercepharma.com/pharma/abbott-and-enanta-present-positive-initial-results-from-phase-2-study-of-abt-450-r-for", "hostname": "fiercepharma.com", "description": "ABBOTT PARK, Ill. and WATERTOWN, Mass., Nov. 1, 2010 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and Enanta Pharmaceuticals today announced positive results from a Phase 2 study of ABT-450/r, an | ABBOTT PARK, Ill. and WATERTOWN, Mass., Nov. 1, 2010 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and Enanta Pharmaceuticals today announced positive results from a Phase 2 study of ABT-450/r, an", "sitename": "FiercePharma", "date": "2010-11-01", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}